Suchergebnisse - "Wagner, Kathryn R"

PubPharm (7)

1

Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy : a phase 2 trial of domagrozumab

enthalten in: Journal of neurology | 2022

von Sherlock, S. | Palmer, J. | Wagner, K. | +13

2

Home-based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type R2 and facioscapulohumeral muscular dystrophy

enthalten in: Muscle & nerve | 2022

von Gidaro, T. | Gasnier, E. | Annoussamy, M. | +9

3

Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping : A randomized, double-blind, placebo-controlled, dose-titration trial

enthalten in: Muscle & nerve | 2021

von Wagner, K. | Kuntz, N. | Koenig, E. | +4

4

Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping : PROMOVI Trial

enthalten in: Journal of neuromuscular diseases | 2021

von McDonald, C. | Shieh, P. | Abdel-Hamid, H. | +12

5

Bone health in facioscapulohumeral muscular dystrophy : A cross-sectional study

enthalten in: Muscle & nerve | 2017

von Chagarlamudi, H. | Corbett, A. | Stoll, M. | +6

6

Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy

enthalten in: Muscle & nerve | 2017

von Eichinger, K. | Heatwole, C. | Heininger, S. | +7

7

A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy

enthalten in: Annals of neurology | 2008

von Wagner, K. | Fleckenstein, J. | Amato, A. | +21

CommentIn: Ann Neurol. 2008 May;63(5):543-5. - PMID 18481287

1
[1]